Author

Dorothea Holzwarth

Observed name: D. Holzwarth

Institution: University Hospital Bonn

Observed institutions: University of Bonn, Medical University of Graz, University Hospital Bonn, Kepler Universitätsklinikum

ORCID: 0000-0003-3533-533X

Observed ORCID: 0000-0003-3533-533X

OpenAlex ID: A5085715982

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy

2024 · Oliver Schwartz, Katharina Vill, et al. · Archives of Pediatrics and Adolescent Medicine · 84

Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy

2022 · Astrid Pechmann, Max Behrens, et al. · Brain · 80

Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec –A Single Centre Experience

2021 · Johannes Friese, Stephanie Geitmann, et al. · Journal of Neuromuscular Diseases · 70

Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study

2022 · Astrid Pechmann, Max Behrens, et al. · Orphanet Journal of Rare Diseases · 45

Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial

2025 · Thomas O Crawford, Laurent Servais, et al. · The Lancet Neurology · 34

Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec

2025 · Dorothea Holzwarth, Gabriele Calaminus, et al. · Molecular Therapy · 9

Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry

2025 · Cornelia Voigt-Müller, Michelle Pfaffenlehner, et al. · Brain · 3

Whole-Exome sequencing identifies GYS2 biallelic variants in individuals with suspected epilepsy

2023 · Muhammad Ilyas, Dorothea Holzwarth, et al. · Seizure · 3

Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland – part II – expert based recommendations for surveillance and management of side-effects

2026 · Andreas Ziegler, Claudia Weiß, et al. · Journal of Neuromuscular Diseases · 1

Real-World Outcomes of Risdiplam in 5q Spinal Muscular Atrophy Over 30 Months in Adolescents and Adults: A Multicentre, Prospective, Observational SMArtCARE Study

2026 · Maggie C. Walter, Markus Weiler, et al. · SSRN Electronic Journal

Evolution of neuroimaging features in children with acute flaccid myelitis compared to other forms of childhood myelitis

2025 · Guido Goj, Jelte Helfferich, et al. · European Journal of Paediatric Neurology

MRI Imaging in 15 Children with Acute Flaccid Myelitis, Baseline and Follow-Up

2024 · G. Goj, J. Helfferich, et al. · Neuropediatrics

Works count: 13

Citation count: 330

H-index: 6

I10-index: 5